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ABStRACt
Nasopharyngeal carcinoma of undifferentiated type is an endemic cancer with a high incidence in Southern 
China, Taiwan, and Singapore, followed by North African countries and Alaska. Despite intensive definitive 
treatment, regrettably about 30% of patients still suffer from loco-regional relapse or even distant metastasis. 
Palliative chemotherapy has been the standard treatment for those whose disease is not amenable to further 
radical surgery or a second course of radiotherapy. Though mainly given with palliative intent, this form of 
chemotherapy can achieve excellent symptom control and prolong survival. More recently targeted therapy 
has also been widely evaluated in metastatic nasopharyngeal carcinoma. Here we provide a comprehensive 
review on the use of various types of palliative chemotherapy and targeted therapy for recurrent and metastatic 
nasopharyngeal carcinoma by searching the MEDLINE and PubMed databases from 1980 to March 2013. 
The key words used were “nasopharyngeal”, “nasopharynx”, “recurrent”, “metastatic”, “chemotherapy”, 
“targeted therapy”, and “immunotherapy”.  

















Undifferentiated	nasopharyngeal	 carcinoma	 (NPC)	 is	
an	endemic	cancer	with	a	high	 incidence	 in	Southern	
China,	Taiwan,	 and	Singapore,	 and	a	 lower	 incidence	
in	North	African	countries	 and	Alaska.	Radiotherapy	
is	 the	mainstay	of	 treatment	 for	 early	 stage	NPC,	
while	 concurrent	 chemoradiation	 is	 indicated	 for	
locoregionally	 advanced	disease,	 as	 revealed	by	
previous	phase	 III	 randomised	controlled	 trials	 and	a	
recent	meta-analysis.1	Nevertheless,	about	30%	of	cases	
relapse	 locoregionally	or	distantly,	despite	 intensive	
definitive	 treatment.2	Though	most	of	 these	 relapsed	
patients	have	an	unfavourable	 survival	outcome,	 their	
survival	 can	be	 significantly	prolonged	with	palliative	
chemotherapy	and	more	 recently	 targeted	 therapy	has	
demonstrated	encouraging	objective	 responses	and	
treatment	outcomes.	In	this	article,	we	comprehensively	








“metastatic”,	 “chemotherapy”,	 “targeted	 therapy”,	 and	
“immunotherapy”	were	used	for	the	literature	search.
PAlliAtivE CHEMOtHERAPy
Although	well	 established	as	 a	 standard	 treatment	 for	
metastatic	NPC,	 there	have	been	no	 randomised	 trials	
comparing	efficacy	of	different	 chemotherapeutic	
regimens	and	no	evidence	pertaining	 to	prolongation	
of	 survival	 compared	 to	 best	 supportive	 care.3	
Apart	 from	 that,	quality-of-life	 assessment	during	
chemotherapy	 is	often	 ignored	 in	 these	 retrospective	
or	phase	 II	 studies.	Moreover,	 the	majority	are	 small-


















between	4	and	14	months.8-13	Docetaxel,	 as	 a	 single	
agent,	 also	produced	a	 response	 rate	of	37%	and	a	
median	PFS	of	5	months.14
Doublet Chemotherapy
Platinum	doublets	 are	 regarded	 as	 the	 principal	
treatment	modality	 for	medically	 fit	patients	with	
metastatic	NPC.	Clinical	 trials	 entailing	platinum	
doublets	have	exhibited	 response	 rates	 from	20	 to	




Median PFS Median OS
Dugan et al5 Ph II 108 R + M pretreated Mitoxantrone 25 NR 4.5 months 13 months
Au et al6 Ph II 24 M untreated Paclitaxel 21.7 0 7.5 months 12 months
Poon et al7 Ph II 28 M pretreated Irinotecan 14 0 3.9 months 11.4 months










Ma et al9 Retrospective 18 R + M untreated 
and pretreated
Gemcitabine 34 6 31% (1 month) 48% (1 year)
Chua et al10 Ph II 17 R + M pretreated Capecitabine 23.5 5.9 4.9 months 7.6 months
Chua et al11 Retrospective 49 R + M pretreated Capecitabine 37 6 5 months 14 months; 
54% (1 year)
Ciuleanu et al12 Ph II 26 R + M pretreated Capecitabine 48 9 14 months 62% (1 year)
Zhang et al13 Ph II 32 pretreated Gemcitabine 43.8 0 5.1 months 16 months; 
63% (1 year)
Ngeow et al14 Ph II 30 R + M pretreated Docetaxel (weekly) 37 0 5.3 months 12.8 months
Table 1. Monochemotherapy in recurrent and / or metastatic nasopharyngeal carcinoma with or without pretreatment.
Abbreviations: CR = complete response; M = metastatic; NR = not reported; OR = objective response; OS = overall survival;  




disease	only	 responded	 to	cisplatin	and	5-FU	 (Table	
2).9,15-36	Platinum	and	5-FU	combination	 therapy	 is	 the	
most	popular	among	doublet	regimens	widely	practised	
in	Asian	countries	where	 the	disease	 is	 endemic.	The	





al17	 revealed	 that	 all	patients	with	 locally	 recurrent	









5-FU	 followed	by	 radiotherapy	who	 then	developed	
metastatic	disease	with	disease-free	 intervals	greater	
than	1	year	 still,	 nevertheless,	 responded	 to	 the	 same	
regimen.17	Moreover,	 the	 toxicity	profile	 is	generally	
favourable	with	mild	immunosuppression	and	peripheral	
neuropathy.	However	cisplatin-induced	nephrotoxicity	








of	 these	 showed	cisplatin	conferred	 superior	disease-
free	 survival	 and	overall	 survival	 (OS)	compared	 to	
carboplatin	when	both	were	used	with	5-FU.39	However	
this	 study	did	not	 recruit	patients	with	 recurrent	or	
metastatic	diseases.	More	recently,	carboplatin	has	been	
tested	with	concurrent	chemoradiation	against	cisplatin-
based	concurrent	 chemoradiation	 in	a	 randomised	
controlled	non-inferiority	 study.40	Patients	with	 locally	
advanced	NPC	were	 randomised	 to	 receive	cisplatin	
chemoradiation	versus	carboplatin	chemoradiation	




Author(s) Study No. of 
patients




Median PFS Median OS
Wang and Tan15 Retrospective 25 M Cisp + 5-FU 76 8 NR NR
Au and Ang16 Ph II 24 R + M Cisp + 5-FU 66 13 8 months 11 months
Chi et al17 Ph II 20 R
15 M








Stein et al18 Ph II 18 R + M Cisp + Ifos 59 15 NR NR
Yeo et al19 Ph II 42 M Carbo + 5-FU 38 17 NR 12.1 months
Yeo et al20 Ph II 27 R + M Carbo + Pac 59 11 6 months 13.9 months
Tan et al21 Ph II 32 M Carbo + Pac 75 3 7 months 12 months
Ciuleanu et al22 Ph II 40 M Carbo + Pac 27.5 7.5 3.5 months 11.5 months
Ngan et al23 Ph II 44 R + M Cisp + Gem 73 20 10.6 months 15 months
Ma et al9 Ph II 14 R + M Cisp + Gem 64 14 13% (1 year) 68% (1 year)
Wang et al24 Retrospective 75 R + M Cisp + Gem 42.7 5.3 5.6 months 9 months
Ma et al25 Ph II 40 R + M Oxali + Gem 56.1 0 9 months 19.6 months
McCarthy et al26 Ph II 9 R + M Cisp + Doc 22 0 8.4 months 76% (1 year)
Chua et al27 Ph II 19 M Cisp + Doc 62.5 6.3 5.6 months 12.4 months
Li et al28 Ph II 48 M Cisp + Cape 62.5 6.3 7.7 months 13.3 months
Chua et al29 Ph II 18 R + M Ifos + 5-FU / LV 56 6 6.5 months 51% (1 year)
Huang et al30 Ph II 34 R + M Ifos + Doc 67.6 14.7 6 months NR
Altundag et al31 Ph II 21 R + M Ifos + Doc 33.3 0 7 months NR
Wang et al32 Ph II 39 M Gem + Vino 36 3 5.6 months 11.9 months
Dede et al33 Retrospective 30 R + M Ifos + Doxo 30 0 4 months (median TTP) NR
Chen et al34 Ph II 61 R + M Gem + Vino 37.7 1.6 5.2 months 14.1 months
Yau et al35 Ph II 15 R + M Cisp + Pem 20 7 30 weeks (median TTP) NR
Chua et al36 Ph II 44 M Cisp + Cape 53.8 2.6 7.3 months (median TTP) 28.0 months
Table 2. Doublet chemotherapy regimens in recurrent and / or metastatic nasopharyngeal carcinoma with or without pretreatment.
Abbreviations: Cape = capecitabine; Carbo = carboplatin; Cisp = cisplatin; CR = complete response; Doc = docetaxel; Doxo = doxorubicin; 
5-FU = 5-fluorouracil; Gem = gemcitabine; Ifos = ifosphamide; LV = leucovorin; M = metastatic; NR = not reported; OR = objective response; 
OS = overall survival; Oxali = oxaliplatin; Pac = paclitaxel; Pem = pemetrexed; PFS = progression-free survival; Ph II = phase II; R = recurrent; 
TTP = time to progression; Vino = vinorelbine.
VHF	Lee	and	DLW	Kwong
Hong	Kong	J	Radiol.	2013;16:252-60	 255
In	2013,	 a	 retrospective	Malaysian	 study	compared	
cisplatin	and	5-FU	with	carboplatin	and	5-FU	 in	41	
patients	with	 recurrent	 and	metastatic	 squamous-cell	




were	 that	no	 subgroup	analysis	was	performed	 for	
NPC	patients	only	and	there	were	six	treatment-related	
mortalities	 (14.6%)	—	four	 in	 the	carboplatin	+	5-FU	
group	and	two	in	the	cisplatin	+	5-FU	group.
Other	 active	 agents	 for	 recurrent	 and	metastatic	
NPC	 include	gemcitabine,	 capecitabine,	oxaliplatin	
and	 taxanes.42	One	 study	published	 in	2002	 tested	
gemcitabine	with	platinum	as	 first-line	chemotherapy	
for	metastatic	NPC	 in	44	patients	 and	was	carried	out	






























chemotherapy,	which	was	 likely	due	 to	 side-effects	








metastatic	NPC.35	When	used	with	 regular	 folic	 acid	
and	vitamin	B12	 supplements,	pemetrexed	per	 se	has	
very	 limited	 treatment-related	 side-effects.	Fifteen	
patients	were	 recruited	 into	 this	 study,	 six	of	whom	




the	 rest	 received	cisplatin	during	 their	 initial	definitive	
chemoradiation.	Serum	biochemistry	 for	Epstein-Barr	
virus	 (EBV-DNA)	was	also	monitored	as	 a	 surrogate	
tumour	marker.	The	OR	rate	was	20%	and	one	patient	
(7%)	enjoyed	complete	 remission.	Another	 eight	
patients	 (53%)	had	 their	disease	 stabilised,	giving	






treatment.	As	persistent	 and	 irreversible	 treatment-
related	 toxicity	often	precludes	 long-term	use	of	




re-challenged	with	cisplatin	 if	 they	were	exposed	 to	
it	during	previous	 induction	chemotherapy,	definitive	
cisplatin-based	chemoradiation	or	prior	palliative	
chemotherapy.	An	older	 study	 revealed	 that	 all	 four	
patients	with	a	disease-free	interval	of	more	than	1	year	
after	 induction	cisplatin	and	5-FU	and	 radiotherapy	
still	 responded	 to	 the	 same	 regimen.17	 In	 their	 study	
on	doublet	 regimen	using	cisplatin	and	capecitabine	
for	previously	untreated	metastatic	NPC,	Chua	et	
al36	demonstrated	 that	prior	 adjunctive	 (neoadjuvant,	
concurrent,	or	 adjuvant)	 chemotherapy	given	at	 least	
6	months	before	 study	entry	had	a	 longer	PFS	 (9	vs.	
7	months)	 and	OS	 (30	vs.	28	months),	 though	 the	
differences	were	not	 statistically	 significant.	Recently,	
molecular	medicine	has	played	an	 important	 role	 in	
the	prediction	of	 chemosensitivity.	Some	 light	has	









with	 ERCC1,	XPF	 forms	 a	 heterodimer	which	
functions	as	 a	 structure-specific	 endonuclease.	The	
ERCC1	also	binds	and	stabilises	XPF,	which	enhances	
the	 latter’s	 endonuclease	 to	create	an	 incision	5’	 to	
the	DNA	 lesion,	 thus	allowing	DNA	 to	be	 repaired.	




setting.43-46	Another	 study	 showed	 that	high	ERCC1	
levels	predicted	poor	 locoregional	 control,	but	did	
not	predict	 resistance	 to	cisplatin.47	One	more	 recent	
study	 showed	 that	neither	ERCC1	nor	XPF	predicted	
locoregional	 recurrence,	disease-free	 survival	 and	OS	
in	142	patients	with	NPC	treated	with	curative	intent.48	
Perhaps	one	of	the	solutions	to	these	conflicting	results	



















toxicity,	 and	 the	 interval	 to	 recurrence	after	previous	
platinum-based	 regimen.	Re-challenge	with	cisplatin	
and	5-FU	can	be	considered	 in	patients	who	enjoyed	
a	good	 initial	 response	 to	 the	 same	 regimen	with	an	
intervening	disease-free	period	of	more	 than	1	year.	
Carboplatin	 is	 an	acceptable	 substitute	producing	
similar	 responses	and	outcomes	when	cisplatin	 is	









Several	 trials	 reported	on	 the	polychemotherapy	 for	
recurrent	NPC	and	demonstrated	encouraging	response	
rates	but	 also	more	 treatment-related	 toxicities	 (Table	
3).49-56	More	importantly,	they	have	not	been	compared	
with	 the	 standard	5-FU	+	cisplatin	doublet	 regimen.	









Author(s) Study No. of patients Regimens OR (%) CR (%) Median PFS Median OS
Boussen et al49 Ph II 49 R + M untreated and 
pretreated 
Cisp + B + 5-FU 79 19 50 months NR
Su et al50 Ph II 25 R + M Cisp + B + 5-FU 40 3 NR NR
Azli et al51 Ph II 44 R + M pretreated and not BEC (B + Epi + Cisp) 45 20 53 months NR










Taamma et al53 Ph II 23 R + M FBEC (5-FU + B + Epi + Cisp) 78 39 42 months NR
Hasbini et al54 Ph II 44 R + M FMEP (5-FU + mitomycin + Epi 
+ Cisp)
52 13 9 months 14 months
Leong et al55 Ph II 28 M Carbo + Gem + Pac + 5-FU / LV 86 11 8 months 22 months
Huang et al56 Ph II 56 R + M DCF (Doc + Cisp + 5-FU) 72.5 9.8 NR NR
Table 3. Results for polychemotherapy in recurrent and / or metastatic nasopharyngeal carcinoma with or without pretreatment.
Abbreviations: B = bleomycin; CAPABLE: Cyclophospamide + Bleomycin + Doxorubicin + Cisplatin; Carbo = carboplatin; Cisp = cisplatin; CR 
= complete response; Doc = docetaxel; Epi = epirubicin; 5-FU = 5-fluorouracil; Gem = gemcitabine; Ifos = ifosphamide; LV = leucovorin; M = 
metastatic; NR = not reported; OR = objective response; OS = overall survival; Pac = paclitaxel; PFS = progression-free survival; Ph II = phase 





therapy	 for	metastatic	NPC.	First	of	 all,	 like	other	
squamous-cell	 head	and	neck	cancers,	 epidermal	
growth	factor	receptor	(EGFR)	is	also	highly	expressed	
in	NPC.57-59	Thus,	 a	 few	studies	 investigated	 the	 role	
of	EGFR	 tyrosine	kinase	 inhibitors	 and	monoclonal	
antibodies	 in	metastatic	NPC.	A	small	phase	 II	 study	
from	Hong	Kong	showed	 that	none	of	19	patients	
responded	after	gefitinib	in	previously	heavily	pretreated	
NPC,	with	median	values	 for	 time	 to	progression	and	
OS	of	4	and	16	months,	 respectively.60	Another	Hong	






appeared	 to	be	no	better	 than	geftinib	 in	metastatic	
NPC.	Use	of	cetuximab,	a	monoclonal	antibody	against	
EGFR,	 in	 combination	with	 carboplatin	was	also	
tested.	Seven	(12%)	out	of	59	patients	enjoyed	a	partial	
response	with	a	median	PFS	of	3	months	and	median	
OS	of	8	months,	but	 at	 the	expense	of	 significant	
toxicity	(grade	≥3	toxicities	in	52%	of	the	patients).63
Vascular	 endothelial	growth	 factor	 (VEGF)	and	 its	
receptor	(VEGFR)	is	also	a	potential	target	of	treatment	
in	NPC.	Its	overexpression	was	found	in	60	to	67%	of	
patients	 and	also	conferred	a	 shorter	 survival.64,65	The	
use	of	 sorafenib,	 an	oral	multikinase	 inhibitor,	was	
also	not	 shown	 to	be	more	efficacious	 than	 systemic	
chemotherapy.66	A	more	 recently	published	phase	
II	 study	on	 sorafenib	 in	combination	with	 standard	





by	a	high	 frequency	of	hand-foot-skin	 reactions	 (83%	
in	all	 and	19%	 in	grade	≥3),	 leucopenia	 (78%	 in	all	
and	7%	in	grade	≥3),	and	haemorrhagic	events	(22%	in	
all	 and	2%	 in	grade	≥3).	Another	multikinase	 tyrosine	






29%	 in	grade	3/4,	 and	14%	 in	grade	5)	 and	 included	
epistaxis,	haemoptysis,	 and	haematemesis	 in	6,	3,	 and	
2	patients,	 respectively.	Two	patients	with	 tumour	
invasion	 to	 the	carotid	sheath	suffered	a	fatal	epistaxis	
/	haematemesis	which	was	 likely	 secondary	 to	carotid	
blowout	after	 tumour	 shrinkage.	Pazopanib,	 another	
orally	available	multikinase	inhibitor	against	VEGFR-1,	




disease.	Treatment	was	 fairly	 tolerated;	 fatigue	and	
hand-foot	 syndrome	were	 the	commonest	grade	≥3	
toxicities.	One	patient	died	of	epistaxis	and	myocardial	






accrue	 in	a	metastatic	 setting	will	depend	on	 results	
from	future	studies.
New	genes	and	 /	or	growth	 factor	pathways	have	
been	 identified	as	potential	 targets	of	new	 targeted	
therapies.	For	 instance,	 the	PI3K/Akt	pathway	was	
recently	 revealed	 to	be	 frequently	 involved	 in	NPC	




nasopharyngeal	 tissues.73-78	A	 local	 study	 found	 that	
upregulation	of	miRNA-144	promoted	malignant	
progression	by	 repressing	 the	expression	of	 a	 tumour	
suppressor	gene	phosphatase	and	 tensin	homologue	
(PTEN),	which	is	partially	responsible	for	upregulation	
of	 the	PI3K/Akt	pathway	 in	NPC.65	 In-vitro	cell-line	
studies	have	demonstrated	 that	Akt	 inhibitors	 can	
suppress	tumour	growth.	Hopefully	the	efficacy	of	these	
inhibitors	 can	be	 further	verified	 in	phase	 II	 and	 III	
clinical	trials.79,80
CONClUSiON
In	 summary,	 a	platinum-based	chemotherapy	 regimen	
especially	cisplatin	and	5-FU	is	still	 the	principal	first-
line	treatment	for	recurrent	/	metastatic	NPC.	Cisplatin	
is	preferred	over	 carboplatin	based	on	 its	 long	history	
with	much	accumulated	experience	by	oncologists.	
However,	other	 factors	 including	 the	 toxicity	profile	
of	 chemotherapy,	 renal	 function,	 and	 length	of	 stay	 in	










to	doublet	 regimens.	The	 role	of	 targeted	 therapy	 in	
NPC	 is	 still	 evolving.	New	 targets	 and	growth	 factor	
pathways	have	been	gradually	 identified	and	new	
compounds	against	 these	 targets	 are	awaited.	Current	
attention	 is	 also	 focused	on	 immunotherapy,	using	
autologous	EBV-specific	 cytotoxic	T-lymphocytes	
(CTLs)	targeting	the	antigens	of	EBV	including	EBNA-
1,	 latent	membrane	protein-1	 (LMP-1)	and	 latent	
membrane	protein-2	(LMP-2).81,82	Previous	pilot	studies	






vector-based	vaccine	 (AdE1-LMPoly)	 that	 encodes	
multiple	CTL	epitones	from	LMP1	and	LMP2	are	also	
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